ESR1 and breast cancer: Since both ER status and proliferation are critical factors for determining patient prognosis in breast cancer, we postulated that prognosis could be better predicated based on a combination of iRASMCF-7 and iRASMDA. Specifically, we divided the patients into four categories based on both iRASMCF-7 and iRASMDA (Figure 5E).